BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020 07:30 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
January 02, 2020 08:15 ET
|
BeiGene, LTD.
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies
December 27, 2019 22:30 ET
|
BeiGene, LTD.
Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophages BEIJING, China and...
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia
December 16, 2019 07:00 ET
|
BeiGene, LTD.
- Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)-...
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019
December 13, 2019 07:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting
December 08, 2019 16:45 ET
|
BeiGene, LTD.
Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma Poster presentation on data from clinical trial of BRUKINSA combined with...
BeiGene Reports Third Quarter 2019 Financial Results
November 12, 2019 16:05 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting
November 06, 2019 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Global Strategic Oncology Collaboration with Amgen
October 31, 2019 16:00 ET
|
BeiGene, LTD.
• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China • Companies to Jointly Develop 20 Amgen Oncology Pipeline...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud: Investors Who Suffered Losses Encouraged to Contact Firm
October 29, 2019 20:02 ET
|
Hagens Berman Sobol Shapiro LLP
Class-action law firm urges BGNE investors who have suffered significant losses to submit your loss now to learn if they qualify to recover their investment losses. SAN FRANCISCO, Oct. 29, 2019 ...